Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Niclosamide Formulations for the Treatment of Influenza Infections - Project Summary the Principal Goal of This Project Is to Demonstrate That the Fda-approved Anthelminthic Drug, Niclosamide, Can Be Reformulated in a Synthetic Lung Surfactant Which Can Be Aerosolized for the Treatment of Infections Caused by Respiratory Viruses. the Studies Proposed in This Sbir Phase I Application Will Be Focused on Testing This Concept by Suspending Niclosamide Loaded Liposomes in Our Proprietary Lung Surfactant Technology (niclosurf) and Testing Candidate Niclosurf Formulations in a Mouse Influenza Challenge Model. the Effectiveness of Niclosurf as a Treatment for Respiratory Viral Infections Caused by Influenza Will Be Evaluated.
Committed
$298,479
Paid out
$275.9K
92%
Committed, not yet paid
$22.6K
8%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…